Dapsone 5% and erythromycin 2% significantly reduce inflammatory lesion counts in acne vulgarisTrial shows specific antibiotics help treat certain types of acne

This network meta-analysis evaluated the efficacy of various topical antibiotic monotherapies for the management of acne vulgaris. The analysis included a large aggregate population of 22,645 patients across multiple studies to compare different topical agents against placebo or other topical antibiotics. The primary outcome measured was discontinuation due to adverse events; however, results for this specific endpoint showed significant heterogeneity, necessitating cautious clinical interpretation regarding the safety profile and tolerability of these agents.

The interventions evaluated included dapsone 5%, erythromycin 2%, azithromycin 2%, metronidazole 2%, minocycline 4%, clindamycin 1%, and GDC 268 lotion. These were compared against placebo or other topical antibiotics to determine their specific impact on inflammatory, non-inflammatory, and total lesion counts, as well as overall treatment success.

Regarding primary outcomes for specific lesion types, dapsone 5% showed a significant reduction in inflammatory lesion counts compared to placebo with an effect size of -29.8 (95% CI [-55.4 to -4.1]). Similarly, erythromycin 2% significantly reduced inflammatory lesions with an effect size of -24.0 (95% CI [-45.7 to -2.1]). For non-inflammatory lesion counts, several agents showed significant reductions compared to placebo: azithromycin 2% (-58.9; 95% CI [-85.5 to -31.7]), erythromycin 2% (-42.0; 95% CI [-69.8 to -14.0]), metronidazole 2% (-14.6; 95% CI [-20.8 to -8.6]), and minocycline 4% (-5.1; 95% CI [-9.2 to -2.2]).

In contrast, the analysis found that no treatment showed a significant improvement in total lesion counts compared to placebo. Regarding Investigator's Global Assessment (IGA) for treatment success (defined as a 2-grade reduction), clindamycin 1% (1.6; 95% CI [1.1 to 2.3]), GDC 268 lotion (2.2; 95% CI [1.1 to 4.4]), and minocycline 4% (2.2; 95% CI [1.5 to 3.5]) were found to be superior compared to placebo.

Safety data for these topical treatments exhibited significant heterogeneity, which limits the ability to draw firm conclusions regarding specific adverse event rates or tolerability profiles across all drugs. This variability suggests that while some agents show statistically significant reductions in specific lesion types, the overall safety profile of the class is not uniformly established in this analysis.

Methodologically, the study was limited by inconsistent reporting for Investigator's Global Assessment, which restricted the analysis of IGA improvements to only three specific drugs. These limitations may impact the generalizability of the findings regarding the broader range of available topical antibiotics.

Clinically, these results suggest that while certain monotherapies like dapsone and erythromycin are effective for inflammatory lesions, and others like clindamycin or minocycline show IGA improvements, routine antibiotic monotherapy should be limited in the management of acne vulgaris. This recommendation is based on the inconsistent efficacy observed across total lesion counts and ongoing concerns regarding the development of antibiotic resistance. Questions remain regarding the long-term safety profiles of these agents due to high heterogeneity and the specific impact of combination therapies versus monotherapy, which was not the primary focus of this analysis.